Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $8,534,014.58 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 184,639 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $2,664,412.86.
• On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.61, for a total value of $2,165,637.06.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total value of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.68, for a total value of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14.

Sionna Therapeutics Trading Up 5.3%

SION opened at $43.12 on Thursday. The company’s fifty day moving average price is $39.11 and its two-hundred day moving average price is $39.51. Sionna Therapeutics, Inc. has a 1-year low of $11.77 and a 1-year high of $48.44. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -22.34 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, equities analysts forecast that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SION. Viking Global Investors LP grew its stake in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the period. Jennison Associates LLC raised its stake in shares of Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after buying an additional 41,797 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Sionna Therapeutics by 30.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock valued at $34,203,000 after buying an additional 193,613 shares during the period. Finally, State Street Corp grew its position in Sionna Therapeutics by 188.7% during the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after buying an additional 453,196 shares during the period.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Sionna Therapeutics and kept a $58 price target, implying meaningful upside from recent trading levels and reinforcing optimism around the company’s clinical pipeline. Article Title
• Positive Sentiment: Sionna Therapeutics said management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, which can give investors a fresh update on the company’s cystic fibrosis programs and keep attention on the story. Article Title
• Neutral Sentiment: In its first-quarter update, the company said enrollment is complete in the PreciSION CF Phase 2a trial for SION-719 and that topline data is expected in summer 2026, while the SION-451 Phase 1 study is also on track. It also reported a strong cash balance of about $289.9 million, supporting operations into 2028. Article Title
• Negative Sentiment: Sionna reported a first-quarter loss of $0.60 per share, wider than the expected $0.52 loss, which may weigh on sentiment even though the company remains pre-revenue and focused on clinical development. Article Title
• Negative Sentiment: Director OrbiMed Advisors and director Peter A. Thompson disclosed several large share sales in recent days. The transactions were made under pre-arranged 10b5-1 plans, but the size of the selling can still pressure investor sentiment. Article Title

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Citizens Jmp began coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Wedbush started coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.